southern african guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring hiv-1 infection

Clicks: 279
ID: 246737
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #27 of 77 articles by views in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The Southern African HIV Clinicians Society published its first set of oral pre-exposure prophylaxis (PrEP) guidelines in June 2012 for men who have sex with men (MSM) who are at risk of HIV infection. With the flurry of data that has been generated in PrEP clinical research since the first guideline, it became evident that there was a need to revise and expand the PrEP guidelines with new evidence of safety and efficacy of PrEP in several populations, including MSM, transgender persons, heterosexual men and women, HIV-serodiscordant couples and people who inject drugs. This need is particularly relevant following the World Health Organization (WHO) Consolidated Treatment Guidelines released in September 2015. These guidelines advise that PrEP is a highly effective, safe, biomedical option for HIV prevention that can be incorporated with other combination prevention strategies in Southern Africa, given the high prevalence of HIV in the region. PrEP should be tailored to populations at highest risk of HIV acquisition, whilst further data from studies in the region accrue to guide optimal deployment to realise the greatest impact regionally. PrEP may be used intermittently during periods of perceived HIV acquisition risk, rather than continually and lifelong, as is the case with antiretroviral treatment. Recognition and accurate measurement of potential risk in individuals and populations also warrants discussion, but are not extensively covered in these guidelines.
Reference Key
bekker2016southernsouthern Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Linda-Gail Bekker;Kevin Rebe;Francois Venter;Gary Maartens;Michelle Moorhouse;Francesca Conradie;Carole Wallis;Vivian Black;Beth Harley;Robyn Eakle
Journal Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Year 2016
DOI
10.4102/sajhivmed.v17i1.455
URL
https://sajhivmed.org.za/index.php/hivmed/article/view/455
Keywords
pre-exposure prophylaxis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.